PROKIDNEY CORP. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.305 USD | +8.73% |
|
-22.06% | +19.10% |
| Mar. 25 | ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations | CI |
| Mar. 22 | ProKidney Posts Wider 2023 Loss | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 422.2 | 119.5 | 147 | - | - |
| Enterprise Value (EV) 1 | -68.09 | 119.5 | -5.408 | -148.1 | -117.7 |
| P/E ratio | -29.8 x | -3.12 x | -1.79 x | -5.9 x | -1.99 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | 0.45 x | -0.81 x | 0.03 x | 0.65 x | 0.45 x |
| EV / FCF | 0.86 x | - | 0.06 x | 0.46 x | 0.38 x |
| FCF Yield | 116% | - | 1,683% | 215% | 262% |
| Price to Book | -1.46 x | - | 2.37 x | 1.65 x | 2.32 x |
| Nbr of stocks (in thousands) | 61,540 | 67,137 | 63,923 | - | - |
| Reference price 2 | 6.860 | 1.780 | 2.300 | 2.300 | 2.300 |
| Announcement Date | 3/28/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | -150 | -147.7 | -191.7 | -226.4 | -260.6 |
| EBIT 1 | -153 | -151.5 | -186.9 | -219.3 | -268.7 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -147.2 | -159.5 | -175.2 | -217.4 | -292.3 |
| Net income 1 | -108 | -35.47 | -176.1 | -40.87 | -292.3 |
| Net margin | - | - | - | - | - |
| EPS 2 | -0.2300 | -0.5700 | -1.282 | -0.3900 | -1.154 |
| Free Cash Flow 1 | -78.94 | - | -91 | -319 | -309 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 3/28/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -34.79 | -29.44 | - | - | - | -23.06 | -40.68 | - | - | - | - |
| EBIT 1 | -35.57 | -30.24 | -40.88 | -39.82 | -46.62 | -24.21 | -39.89 | -43.1 | -47.18 | -50.29 | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -25.84 | - | -33.86 | -41.08 | -18.93 | -36.68 | -33.56 | -34.73 | -35.94 | - |
| Net income 1 | -11.93 | -6.487 | -9.665 | -9.118 | -10.98 | -5.701 | -37.78 | -40.28 | -44.37 | -36.43 | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1300 | -0.1100 | - | -0.1400 | -0.1800 | -0.0900 | -0.5300 | -0.5400 | -0.5500 | -0.5700 | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/14/22 | 3/28/23 | 5/11/23 | 8/10/23 | 11/14/23 | 3/22/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 490 | - | 152 | 295 | 265 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | -78.9 | - | -91 | -319 | -309 |
| ROE (net income / shareholders' equity) | - | - | -55.3% | -61% | -56.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | -4.700 | - | 0.9700 | 1.390 | 0.9900 |
| Cash Flow per Share 2 | -1.250 | - | -0.6000 | - | - |
| Capex 1 | 1.85 | - | 50 | 200 | 200 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/28/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.3
USD
Average target price
4.2
USD
Spread / Average Target
+82.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.10% | 147M | |
| +1.77% | 42.86B | |
| +12.24% | 42.74B | |
| +43.96% | 41.36B | |
| -8.83% | 27.68B | |
| +7.44% | 25.15B | |
| -23.01% | 18.63B | |
| +30.56% | 12.37B | |
| -1.82% | 11.92B | |
| +8.35% | 11.21B |
- Stock Market
- Equities
- PROK Stock
- Financials ProKidney Corp.
